References
Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630–637
Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB (2003) Voriconazole. Clin Ther 25:1321–1381
Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571
Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415
Denning DW, Griffiths CE (2001) Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 26:648–653
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vandecasteele, S.J., van Wijngaerden, E. & Peetermans, W.E. Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole. Eur J Clin Microbiol Infect Dis 23, 656–657 (2004). https://doi.org/10.1007/s10096-004-1176-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-004-1176-7